Claims for Patent: 7,687,060

Summary for Patent: 7,687,060

Title:	Method for the treatment or prophylaxis of tuberculosis
Abstract:	The invention provides the use of intravenous immunoglobulin (IVIg) in the preparation of a medicament for the treatment and/or prophylaxis of mycobacterial infection.
Inventor(s):	Jolles; Stephen (Mill Hill, GB), Tascon; Ricardo (Mill Hill, GB), Lowrie; Douglas (Mill Hill, GB), Stavropoulos; Vangelis (Mill Hill, GB)
Assignee:	Medical Research Council (London, GB)
Application Number:	11/371,262
Patent Claims:	1. A method for treating an infection by M. tuberculosis in a subject in need thereof, comprising identifying a subject in need of treatment for M. tuberculosis infection, administering to said subject intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg) or intramuscular immunoglobulin (IMIg), wherein said IVIg, SCIg or IMIg comprises an immunoglobulin mixture from at least 1000 individuals; and determining whether said M. tuberculosis infection has been treated, wherein a reduction in M. tuberculosis titre in said subject by a factor of 10 is indicative of treatment. 2. The method of claim 1, wherein the IVIg, IMIg or SCIg comprises an Immunoglobulin G (IgG) mixture from at least 1000 individuals. 3. The method of claim 1, wherein the IVIg, IMIg or SCIg is at least 90% IgG. 4. The method of claim 1, wherein the IVIg, IMIg or SCIg is human IVIg, IMIg or SCIg. 5. The method of claim 1, wherein the IVIg, IMIg or SCIg is administered intravenously. 6. The method of claim 1, wherein the IVIg, IMIg or SCIg is administered at a dose of 2 g/kg/month. 7. The method of claim 1, wherein the IVIg, IMIg or SCIg is administered in a course of intravenous injections over a period of 2 or more days as a single dose or in repeated doses. 8. The method of claim 1, wherein said IVIg, IMIg or SCIg is administered simultaneously with, prior to, or subsequent to administration of a vaccine. 9. The method of claim 8, wherein said vaccine is the Bacillus Calmette-Guerin vaccine. 10. A method for treating an infection by M. tuberculosis in a subject in need thereof, comprising identifying a subject in need of treatment for M. tuberculosis infection, administering to said subject intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg) or intramuscular immunoglobulin (IMIg), wherein said IVIg, SCIg, or IMIg comprises an immunoglobulin mixture from at least 1000 individuals; and determining whether said M. tuberculosis infection has been treated, wherein a reduction in M. tuberculosis titre in said subject by a factor of 100 or more is indicative of treatment. 11. The method of claim 10, wherein the IVIg, IMIg or SCIg comprises an Immunoglobulin G (IgG) mixture from at least 1000 individuals. 12. The method of claim 10, wherein the IVIg, IMIg or SCIg is at least 90% IgG. 13. The method of claim 10, wherein the IVIg, IMIg or SCIg is human IVIg, IMIg or SCIg. 14. The method of claim 10, wherein the IVIg, IMIg or SCIg is administered intravenously. 15. The method of claim 10, wherein the IVIg, IMIg or SCIg is administered at a dose of 2 g/kg/month. 16. The method of claim 10, wherein the IVIg, IMIg or SCIg is administered in a course of intravenous injections over a period of 2 or more days as a single dose or in repeated doses. 17. The method of claim 10, wherein said IVIg, IMIg or SCIg is administered simultaneously with, prior to, or subsequent to administration of a vaccine. 18. The method of claim 17, wherein said vaccine is the Bacillus Calmette-Guerin vaccine.

Details for Patent 7,687,060

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2023-09-08
Octapharma Pharmazeutika Produktionsges.m.b.h.	CUTAQUIG	immune globulin subcutaneous (human)-hipp	Solution	125668	12/12/2018		2023-09-08